Mannose binding lectin and prediction of risk for chemotherapy induced febrile neutropenia in patients with a solid tumor.
Aged
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Chemotherapy-Induced Febrile Neutropenia
/ blood
Female
Genotype
Humans
Male
Mannose-Binding Lectin
/ blood
Middle Aged
Neoplasms
/ blood
Polymorphism, Genetic
Prognosis
Promoter Regions, Genetic
/ genetics
Prospective Studies
Risk Factors
Febrile neutropenia
MBL- genotype
MBL-deficiency
Mannose-binding lectin (MBL)
Solid tumors
Journal
Cancer investigation
ISSN: 1532-4192
Titre abrégé: Cancer Invest
Pays: England
ID NLM: 8307154
Informations de publication
Date de publication:
2019
2019
Historique:
pubmed:
26
3
2019
medline:
30
4
2019
entrez:
26
3
2019
Statut:
ppublish
Résumé
Mannose-binding lectin (MBL) - deficient patients who undergo chemotherapy for a solid tumor might have an increased risk developing febrile neutropenia (FN). We investigated in a prospective cohort study relations between MBL-serum levels and polymorphisms in MBL promotor genotypes (-550H/L and -221X/Y) on incidence and severity of FN. Risk of FN was 17.9% in MBL-deficient and 22.5% in MBL-sufficient patients (RR = 0.796, p = 0.45). Median MBL serum levels at baseline were respectively 1.39 µg/mL and 1.09 µg/mL (p = 0.92) in patients with and without FN. In conclusion, serum MBL and MBL genotypes (-550H/L and -221X/Y) do not determine the risk for developing FN.
Identifiants
pubmed: 30907154
doi: 10.1080/07357907.2019.1582660
doi:
Substances chimiques
Mannose-Binding Lectin
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM